Zimmer Biomet (ZBH) Competitors $110.61 -0.13 (-0.12%) (As of 12/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ZBH vs. SOLV, SNN, PEN, GKOS, BLCO, STVN, INSP, PRCT, NVST, and AXNXShould you be buying Zimmer Biomet stock or one of its competitors? The main competitors of Zimmer Biomet include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Bausch + Lomb (BLCO), Stevanato Group (STVN), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Envista (NVST), and Axonics (AXNX). These companies are all part of the "medical equipment" industry. Zimmer Biomet vs. Solventum Smith & Nephew Penumbra Glaukos Bausch + Lomb Stevanato Group Inspire Medical Systems PROCEPT BioRobotics Envista Axonics Solventum (NYSE:SOLV) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment. Do analysts rate SOLV or ZBH? Solventum currently has a consensus price target of $68.00, indicating a potential downside of 3.89%. Zimmer Biomet has a consensus price target of $123.22, indicating a potential upside of 11.27%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Zimmer Biomet 2 Sell rating(s) 12 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the MarketBeat Community favor SOLV or ZBH? Zimmer Biomet received 898 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 67.24% of users gave Zimmer Biomet an outperform vote while only 5.88% of users gave Solventum an outperform vote. CompanyUnderperformOutperformSolventumOutperform Votes15.88%Underperform Votes1694.12% Zimmer BiometOutperform Votes89967.24% Underperform Votes43832.76% Do insiders and institutionals hold more shares of SOLV or ZBH? 88.9% of Zimmer Biomet shares are held by institutional investors. 0.7% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, SOLV or ZBH? Zimmer Biomet has higher revenue and earnings than Solventum. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolventumN/AN/AN/AN/AN/AZimmer Biomet$7.60B2.90$1.02B$5.2621.05 Does the media prefer SOLV or ZBH? In the previous week, Zimmer Biomet had 5 more articles in the media than Solventum. MarketBeat recorded 23 mentions for Zimmer Biomet and 18 mentions for Solventum. Solventum's average media sentiment score of 1.56 beat Zimmer Biomet's score of 0.82 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 17 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zimmer Biomet 17 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SOLV or ZBH more profitable? Zimmer Biomet has a net margin of 14.27% compared to Solventum's net margin of 0.00%. Zimmer Biomet's return on equity of 12.95% beat Solventum's return on equity.Company Net Margins Return on Equity Return on Assets SolventumN/A N/A N/A Zimmer Biomet 14.27%12.95%7.55% SummaryZimmer Biomet beats Solventum on 12 of the 13 factors compared between the two stocks. Ad Behind the MarketsHere’s how you could profit from the historic Trump rallyEx-Wall Street CEO crushed the market this year... Giving his readers a chance to outperform the S&P by as much as 164%. Now he's saying Trump's landslide win is opening up a rare window of opportunity.Click to get the name and ticker symbol Get Zimmer Biomet News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBH vs. The Competition Export to ExcelMetricZimmer BiometSurgical appliances & supplies IndustryMedical SectorNYSE ExchangeMarket Cap$22.05B$10.08B$5.21B$20.39BDividend Yield0.86%1.07%5.36%3.43%P/E Ratio21.0521.63119.0442.11Price / Sales2.9032.071,270.0018.10Price / Cash9.1122.6841.9822.41Price / Book1.855.794.885.57Net Income$1.02B$182.72M$119.93M$984.27M7 Day Performance-1.18%-0.13%0.48%0.39%1 Month Performance2.15%7.03%0.58%6.48%1 Year Performance-5.26%-1.76%32.25%23.52% Zimmer Biomet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBHZimmer Biomet4.6707 of 5 stars$110.61-0.1%$123.22+11.4%-6.1%$22.02B$7.60B21.0318,000SOLVSolventum1.7004 of 5 stars$72.20+1.0%$68.00-5.8%N/A$12.47B$8.26B0.0022,000Analyst ForecastPositive NewsSNNSmith & Nephew2.2319 of 5 stars$25.76-0.1%N/A-2.7%$11.26B$5.64B0.0018,452Positive NewsPENPenumbra4.2234 of 5 stars$245.07+0.4%$230.92-5.8%+7.7%$9.41B$1.06B283.864,200Insider TradePositive NewsGKOSGlaukos3.6478 of 5 stars$139.79-2.7%$136.18-2.6%+108.8%$7.71B$314.71M-47.08780Analyst ForecastShort Interest ↑Positive NewsGap DownBLCOBausch + Lomb2.5309 of 5 stars$19.46-1.8%$21.00+7.9%+27.1%$6.85B$4.68B-18.5013,300Analyst DowngradeShort Interest ↓News CoveragePositive NewsGap DownSTVNStevanato GroupN/A€20.27+1.2%N/A-26.8%$5.99B$1.09B41.985,635Analyst ForecastINSPInspire Medical Systems4.6579 of 5 stars$189.04-1.9%$233.58+23.6%+26.6%$5.67B$624.80M180.151,011Short Interest ↑PRCTPROCEPT BioRobotics1.8487 of 5 stars$95.53-0.1%$91.71-4.0%+158.2%$4.99B$199.84M-48.51626Analyst ForecastInsider TradeNVSTEnvista3.936 of 5 stars$22.36+0.3%$20.71-7.4%-8.0%$3.85B$2.50B-2.8712,800Analyst ForecastNews CoverageAXNXAxonics3.1733 of 5 stars$70.98+0.8%$71.00+0.0%+23.4%$3.63B$366.38M-591.45610Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Solventum Competitors Smith & Nephew Competitors Penumbra Competitors Glaukos Competitors Bausch + Lomb Competitors Stevanato Group Competitors Inspire Medical Systems Competitors PROCEPT BioRobotics Competitors Envista Competitors Axonics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ZBH) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A...Investors Alley | SponsoredThis frightening chart explains everything going on in the economy (see photo)Why the wealth gap is getting wider — with the one percenters growing ever richer and ever more powerful, whil...Banyan Hill Publishing | SponsoredThe 2024 TECH RESETAre we on the edge of the biggest ‘TECH RESET’ in decades?InvestorPlace | SponsoredExpert: The most important message you’ll see in 2024The message I'm sharing today could be the most important message of 2024. In short, America is being invad...The Freeport Society | SponsoredMeet the NYSE traded company behind a potentially blockbuster antiviral drugThis public company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market Imag...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zimmer Biomet Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zimmer Biomet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.